MIROCALS: Modifying Immune Response and OutComes in ALS

NCT03039673 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

304

Enrollment

OTHER

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: Riluzole
DRUG: IL-2
DRUG: 5% glucose water solution

Sponsor

Centre Hospitalier Universitaire de Nīmes